MX2017004652A - Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina. - Google Patents

Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina.

Info

Publication number
MX2017004652A
MX2017004652A MX2017004652A MX2017004652A MX2017004652A MX 2017004652 A MX2017004652 A MX 2017004652A MX 2017004652 A MX2017004652 A MX 2017004652A MX 2017004652 A MX2017004652 A MX 2017004652A MX 2017004652 A MX2017004652 A MX 2017004652A
Authority
MX
Mexico
Prior art keywords
thieno
benzo
dihydro
novel
azepine derivative
Prior art date
Application number
MX2017004652A
Other languages
English (en)
Spanish (es)
Inventor
Kazuhiro Ito
Peter John Murray
Stuart Thomas Onions
Euan Alexander Fraser Fordyce
Fraser Hunt Simon
Sherbukhin Vladimir
William BROOKES Daniel
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Publication of MX2017004652A publication Critical patent/MX2017004652A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2017004652A 2014-10-10 2015-10-08 Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina. MX2017004652A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188494 2014-10-10
PCT/GB2015/052944 WO2016055791A1 (en) 2014-10-10 2015-10-08 Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

Publications (1)

Publication Number Publication Date
MX2017004652A true MX2017004652A (es) 2017-06-19

Family

ID=51842340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004652A MX2017004652A (es) 2014-10-10 2015-10-08 Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina.

Country Status (13)

Country Link
US (6) US10189863B2 (enExample)
EP (2) EP3204388B1 (enExample)
JP (2) JP6675407B2 (enExample)
KR (1) KR20170058921A (enExample)
CN (1) CN106852144B (enExample)
AU (1) AU2015329789B2 (enExample)
BR (1) BR112017005104B1 (enExample)
CA (1) CA2957868C (enExample)
EA (1) EA201790796A8 (enExample)
IL (1) IL250823A0 (enExample)
MX (1) MX2017004652A (enExample)
SG (1) SG11201701184WA (enExample)
WO (2) WO2016055791A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6675407B2 (ja) 2014-10-10 2020-04-01 プルモシデ リミテド 新規5,6−ジヒドロ−4H−ベンゾ[b]チエノ−[2,3−d]アゼピン誘導体
WO2016097761A1 (en) 2014-12-18 2016-06-23 Pulmocide Limited 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections
MY197231A (en) 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
MY197217A (en) * 2016-02-03 2023-06-01 Janssen Sciences Ireland Uc Combination products for the treatment of rsv
WO2017175000A1 (en) * 2016-04-08 2017-10-12 Pulmocide Limited Compounds
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
US10752598B2 (en) 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
WO2019006295A1 (en) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
ES3043734T3 (en) 2017-11-13 2025-11-25 Enanta Pharm Inc Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
WO2019199908A1 (en) * 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
CA3133300A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
WO2020210246A1 (en) * 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
IL291834B1 (en) 2019-10-04 2026-02-01 Enanta Pharm Inc Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
IL305189A (en) 2021-02-26 2023-10-01 Enanta Pharm Inc Heterocyclic antiviral compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693635A (en) 1993-07-29 1997-12-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
PT1177176E (pt) 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
EP2240029A4 (en) * 2008-01-07 2012-08-22 Synta Pharmaceuticals Corp COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES
WO2011005842A1 (en) 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds
JP5819305B2 (ja) 2009-10-13 2015-11-24 リガンド・ファーマシューティカルズ・インコーポレイテッド 造血成長因子模倣小分子化合物およびそれらの使用
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ampk-활성화 헤테로시클릭 화합물 및 그의 사용 방법
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP2017523988A (ja) 2014-08-05 2017-08-24 アリオス バイオファーマ インク. パラミクソウイルスを治療するための併用療法
JP6675407B2 (ja) * 2014-10-10 2020-04-01 プルモシデ リミテド 新規5,6−ジヒドロ−4H−ベンゾ[b]チエノ−[2,3−d]アゼピン誘導体
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
MY197217A (en) 2016-02-03 2023-06-01 Janssen Sciences Ireland Uc Combination products for the treatment of rsv
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS

Also Published As

Publication number Publication date
US9926335B2 (en) 2018-03-27
US20180179228A1 (en) 2018-06-28
BR112017005104A2 (pt) 2017-12-05
WO2016055791A1 (en) 2016-04-14
IL250823A0 (en) 2017-04-30
EP3204389A1 (en) 2017-08-16
CA2957868C (en) 2023-02-28
CN106852144B (zh) 2019-08-30
JP2017531038A (ja) 2017-10-19
EP3204388B1 (en) 2018-12-12
US20170305935A1 (en) 2017-10-26
KR20170058921A (ko) 2017-05-29
US9732098B2 (en) 2017-08-15
EA201790796A1 (ru) 2017-09-29
US20180319820A1 (en) 2018-11-08
EP3204389B1 (en) 2019-06-26
JP6675407B2 (ja) 2020-04-01
EA201790796A8 (ru) 2018-10-31
CN106852144A (zh) 2017-06-13
US10273249B2 (en) 2019-04-30
EP3204388A1 (en) 2017-08-16
US20190202841A1 (en) 2019-07-04
SG11201701184WA (en) 2017-03-30
US20170190718A1 (en) 2017-07-06
AU2015329789B2 (en) 2019-09-26
BR112017005104B1 (pt) 2022-08-23
US10189863B2 (en) 2019-01-29
WO2016055792A1 (en) 2016-04-14
US20170355717A1 (en) 2017-12-14
JP2017531039A (ja) 2017-10-19
AU2015329789A1 (en) 2017-03-09
US10035810B2 (en) 2018-07-31
CA2957868A1 (en) 2016-04-14
US10472375B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
BR112017005104A2 (pt) derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina
IL251285A0 (en) 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of viral infection
MX2021002168A (es) Compuestos antivirales.
PL3693367T3 (pl) Tieno[3,2-d]pirymidyny przydatne do leczenia zakażeń syncytialnym wirusem oddechowym
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
WO2015001504A3 (en) Antibody formulations and methods
SG11201502522WA (en) 1,2,4-triazine derivatives for the treatment of viral infections.
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
SG11201702766YA (en) Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
WO2015110491A3 (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
HK1220196A1 (zh) 抗病毒吲哚并[2,3-b]喹喔啉
IN2013MU01985A (enExample)
WO2015130547A8 (en) Bis-cyclic guanidine compound compositions, methods of use and treatment thereof
WO2014177510A3 (en) Polymer conjugates of indolocarbazole compounds in the treatment of pruritus
WO2014121170A3 (en) Antiviral compounds
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
PH12015502703A1 (en) Pharmaceutical compositions
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
MX2015017276A (es) Derivados de hiperforina y su uso en la enfermedad de alzheimer.
WO2017059318A3 (en) Scaphopetalone analogs and their uses
UA98069U (xx) N-(3-ТРИФТОРМЕТИЛФЕНІЛ)-2-(2-ОКСО-3,5a,6,11b-ТЕТРАГІДРО-2Н,5Н-ХРОМЕНО[4',3':4,5]ТІОПІРАНО[2,3-d][1,3]ТІАЗОЛ-3-ІЛ)АЦЕТАМІД, ЩО ПРОЯВЛЯЄ АНАБОЛІЧНУ ТА АНДРОГЕННУ ДІЮ
UA88022U (ru) Способ получения вещества с потенциальными физиологическими свойствами 4,5,6,7-тетрагидро-3н-2-n-(пара-метоксифенациламино)-азепина гидрохлорида